DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s ...

Updated results from BP1001-A obesity and Type 2 diabetes testing from the second stage of pre-clinical testing are as follows: Previously, Bio-Path reported BP1001-A increased insulin sensitivity in ...

Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee monitoring its Phase I clinical trial has unanimously approved opening ...